Drug concentrations in hair and dried blood spots as PrEP adherence metrics during pregnancy and postpartum.
(2024 May 3)
J Infect Dis
Wu L, Kinuthia J, Anderson PL, Baeten JM, Dettinger JC, Gandhi M, Gomez L, John-Stewart G, Marwa MM, Ngumbau N, Otieno F, Omondi P, Odhiambo B, Watoyi S, Pintye J

Exploring adolescent girls and young women's PrEP-user profiles: qualitative insights into differentiated PrEP delivery platform selection and engagement in Cape Town, South Africa.
(2024 May)
J Int AIDS Soc 27(5): e26254
Rousseau E, Sikkema KJ, Julies RF, Mazer K, O'Malley G, Heffron R, Morton JF, Johnson R, Celum C, Baeten JM, Bekker LG

HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
(2024 Mar 14)
Clin Infect Dis
Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, Baeten JM, Liu A, Hoover KW, Celum C, Grinsztejn B, Morris S, Wheeler DP, Mayer KH, Golub SA, Bekker LG, Diabaté S, Hoornenborg E, Myers J, Leech AA, McCormack S, Chan PA, Sweat M, Matthews LT, Grant R, Global F/TDF PrEP Study Team

Acceptability and feasibility of long-term, real-time electronic adherence monitoring of HIV pre-exposure prophylaxis (PrEP) use among young women in Kenya: A mixed methods study.
(2024)
PLoS One 19(3): e0299168
Ogello VA, Rono BK, Ngure K, Sedah E, Thuo NB, Musinguzi N, Baeten JM, Bukusi EA, Mugo NR, Haberer JE

Effect of differentiated direct-to-pharmacy PrEP refill visits supported with client HIV self-testing on clinic visit time and early PrEP continuation.
(2024 Mar)
J Int AIDS Soc 27(3): e26222
Zewdie KB, Ngure K, Mwangi M, Mwangi D, Maina S, Etyang L, Maina G, Ogello V, Owidi E, Mugo NR, Baeten JM, Mugwanya KK